Disclosed is a use of a soluble hyaluronidase composition in the manufacture of a medicament for treating a tumour, wherein the composition comprises a soluble hyaluronidase that is conjugated to a polymer and the soluble hyaluronidase is formulated in the composition for administration of at least 50,000 Units (U) at least twice a week for more than one week.